Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Director Richard A. Young Sells 34,837 Shares

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Director Richard A. Young sold 34,837 shares of the company’s stock in a transaction on Friday, June 28th. The stock was sold at an average price of $5.12, for a total transaction of $178,365.44. Following the completion of the transaction, the director now owns 8,000 shares of the company’s stock, valued at $40,960. The sale was disclosed in a filing with the SEC, which is available at this link.

Syros Pharmaceuticals Price Performance

Shares of Syros Pharmaceuticals stock opened at $5.00 on Thursday. The company has a current ratio of 3.01, a quick ratio of 3.01 and a debt-to-equity ratio of 1.97. The company has a 50-day moving average of $5.30 and a 200 day moving average of $6.08. Syros Pharmaceuticals, Inc. has a 1 year low of $2.09 and a 1 year high of $8.17.

Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($0.79) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.10. Syros Pharmaceuticals had a negative net margin of 1,656.34% and a negative return on equity of 395.36%. During the same period last year, the business posted ($0.85) earnings per share. As a group, analysts anticipate that Syros Pharmaceuticals, Inc. will post -3.19 EPS for the current fiscal year.

Institutional Trading of Syros Pharmaceuticals

Several institutional investors have recently bought and sold shares of SYRS. Virtu Financial LLC purchased a new stake in Syros Pharmaceuticals during the 1st quarter valued at about $64,000. Acadian Asset Management LLC purchased a new stake in Syros Pharmaceuticals during the 1st quarter valued at about $91,000. Assenagon Asset Management S.A. grew its position in Syros Pharmaceuticals by 576.5% during the 1st quarter. Assenagon Asset Management S.A. now owns 169,999 shares of the company’s stock valued at $909,000 after purchasing an additional 144,869 shares during the last quarter. Kennedy Capital Management LLC purchased a new stake in Syros Pharmaceuticals during the 1st quarter valued at about $2,166,000. Finally, Opaleye Management Inc. purchased a new stake in Syros Pharmaceuticals during the 4th quarter valued at about $2,799,000. 91.47% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of Syros Pharmaceuticals in a report on Wednesday, June 26th. StockNews.com upgraded shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 15th. Finally, Piper Sandler restated an “overweight” rating and issued a $13.00 price objective on shares of Syros Pharmaceuticals in a report on Wednesday, April 3rd.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.